SVB Wealth LLC Invests $404,000 in Halozyme Therapeutics, Inc. $HALO

SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,162 shares of the biopharmaceutical company’s stock, valued at approximately $404,000.

Other institutional investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC increased its holdings in Halozyme Therapeutics by 11.6% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 4,031 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 418 shares in the last quarter. RFG Advisory LLC bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $1,535,000. IFP Advisors Inc boosted its holdings in shares of Halozyme Therapeutics by 9.0% during the 2nd quarter. IFP Advisors Inc now owns 3,939 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 324 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 3.7% during the 2nd quarter. Baird Financial Group Inc. now owns 11,087 shares of the biopharmaceutical company’s stock valued at $868,000 after acquiring an additional 393 shares during the last quarter. Finally, Allworth Financial LP grew its stake in shares of Halozyme Therapeutics by 3.9% in the second quarter. Allworth Financial LP now owns 37,664 shares of the biopharmaceutical company’s stock worth $2,948,000 after acquiring an additional 1,420 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 32,478 shares of company stock valued at $3,076,604. Insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Trading Down 0.4%

Halozyme Therapeutics stock opened at $107.00 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The company has a market cap of $12.14 billion, a P/E ratio of 31.94, a P/E/G ratio of 0.42 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business has a 50-day simple moving average of $93.18 and a two-hundred day simple moving average of $76.75.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.